SAGE Therapeutics Inc. (SAGE)

180.26
NASDAQ : Health Technology
Prev Close 187.41
Day Low/High 180.00 / 188.49
52 Wk Low/High 79.88 / 193.56
Avg Volume 394.90K
Exchange NASDAQ
Shares Outstanding 51.15M
Market Cap 9.59B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sage Therapeutics To Report Second Quarter 2019 Financial Results On Tuesday, August 6, 2019

Sage Therapeutics To Report Second Quarter 2019 Financial Results On Tuesday, August 6, 2019

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019, the Compensation Committee of Sage's Board of Directors...

Sage Therapeutics To Host "Sage FutureCast" Webcast

Sage Therapeutics To Host "Sage FutureCast" Webcast

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host "Sage FutureCast: An R&D and Portfolio Review" on Wednesday, July 24, 2019...

Sage Therapeutics To Present At BMO Prescriptions For Success Healthcare Conference

Sage Therapeutics To Present At BMO Prescriptions For Success Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare...

Product Shot (black) (Photo: Business Wire)

Product Shot (black) (Photo: Business Wire)

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019, the Compensation Committee of Sage's Board of Directors...

Sage Therapeutics To Present At Goldman Sachs 40th Annual Global Healthcare Conference

Sage Therapeutics To Present At Goldman Sachs 40th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 40 th Annual Global Healthcare...

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.

Sage Therapeutics To Present At 2019 RBC Capital Markets Global Healthcare Conference

Sage Therapeutics To Present At 2019 RBC Capital Markets Global Healthcare Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare...

Sage Therapeutics To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Sage Therapeutics To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Care...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019, the Compensation Committee of Sage's Board of Directors...

Sage Therapeutics Announces First Quarter 2019 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces First Quarter 2019 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31,...

Sage Therapeutics To Report First Quarter 2019 Financial Results On Thursday, May 2, 2019

Sage Therapeutics To Report First Quarter 2019 Financial Results On Thursday, May 2, 2019

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 1, 2019, the Compensation Committee of Sage's Board of...

A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me

A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me

Let's review the charts this morning.

Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)

Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)

But don't forget, says Jim Cramer, we still need a trade deal with China.

FedEx, Federal Reserve, Google, AMD, Sage Therapeutics - 5 Things You Must Know

FedEx, Federal Reserve, Google, AMD, Sage Therapeutics - 5 Things You Must Know

U.S. stock futures turn lower as investors await a key decision on interest rates from the Federal Reserve; FedEx sinks after issuing its second warning about fiscal 2019 profit; Google's new cloud-based video-game playing and sharing platform, Stadia, will be powered by chips made by Advanced Micro Devices.

Sage Therapeutics Announces FDA Approval Of ZULRESSO™ (brexanolone) Injection, The First And Only Treatment Specifically Indicated For Postpartum Depression

Sage Therapeutics Announces FDA Approval Of ZULRESSO™ (brexanolone) Injection, The First And Only Treatment Specifically Indicated For Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced today the U.

Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug

Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug

First treatment for common childbirth complication wins FDA OK.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2019, the Compensation Committee of Sage's Board of...

Sage Therapeutics Announces Closing Of $575 Million Public Offering Of Common Stock, Including Full Exercise Of Option To Purchase Additional Shares

Sage Therapeutics Announces Closing Of $575 Million Public Offering Of Common Stock, Including Full Exercise Of Option To Purchase Additional Shares

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of...

Sage Therapeutics Prices Public Offering Of Common Stock

Sage Therapeutics Prices Public Offering Of Common Stock

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its...

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500,000,000 of...

Sage Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the fourth quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Report Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 19, 2019

Sage Therapeutics To Report Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 19, 2019

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Appoints Elizabeth Barrett And George Golumbeski To Board Of Directors

Sage Therapeutics Appoints Elizabeth Barrett And George Golumbeski To Board Of Directors

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.

Notable Tuesday Option Activity: SAGE, RESI, EAT

Notable Tuesday Option Activity: SAGE, RESI, EAT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sage Therapeutics Inc , where a total volume of 4,304 contracts has been traded thus far today, a contract volume which is representative of approximately 430,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.5% of SAGE's average daily trading volume over the past month, of 852,990 shares.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results

SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results

Stock doubles in value on positive Stage 3 trial results showing "meaningful" treatment of postpartum depression symptoms.